SHLA-I contamination, a novel mechanism to explain Ex Vivo/In vitro modulation of IL-10 synthesis and release in CD8+ T lymphocytes and in neutrophils following intravenous immunoglobulin infusion

Journal of Clinical Immunology

Volumn 30, Issue 3, 2010, Pages 384-392

  Ghio, Massimo ^a,d   Contini, Paola ^a   Setti, Maurizio ^a   Ubezio, Gianluca ^a   Mazzei, Clemente ^b   Tripodi, Gino ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b Imperia Hospital   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

IL 10; Immunomodulation; IVIG; SHLA I

Indexed keywords

FAS LIGAND; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; INTERLEUKIN 10; MESSENGER RNA; RITUXIMAB; IMMUNOLOGIC FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EX VIVO STUDY; GENE LOCATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; BIOSYNTHESIS; CELL SEPARATION; DRUG CONTAMINATION; DRUG EFFECTS; FATIGUE SYNDROME, CHRONIC; FLOW CYTOMETRY; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOGENICITY; PATHOLOGY; SECRETION (PROCESS); SYSTEMIC VASCULITIS;

CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CELLS, CULTURED; DRUG CONTAMINATION; FAS LIGAND PROTEIN; FATIGUE SYNDROME, CHRONIC; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV; HIV INFECTIONS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERLEUKIN-10; NEUTROPHILS; SYSTEMIC VASCULITIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77953293892     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-009-9364-y     Document Type: Article

References (46)

1. SV Kaveri S Lacroix-Desmazes J Bayry 2008 The antiinflammatory IgG NEJM. 359 307 9 10.1056/NEJMcibr0803649 1:CAS:528:DC%2BD1cXoslGis7c%3D 18635437 (Pubitemid 352008448)
2. J-F Seite Y Shoenfelf P Youinou S Hillion 2008 What is the contents of magic draft IVIg? Autoimmun Rev. 7 435 9 10.1016/j.autrev.2008.04.012 18558358
3. WAC Sewell S Jolles 2002 Immunomodulatory action of intravenous immunoglobulin Immunology 107 387 93 10.1046/j.1365-2567.2002.01545.x 1:CAS:528:DC%2BD38Xps1yqt7k%3D 12460182 (Pubitemid 36693642)
4. MM Eibl 2003 Intravenous immunoglobulins in neurological disorders: safety issues Neurol Sci. 24 S222 6 10.1007/s10072-003-0082-6 14598047 (Pubitemid 37304327)
5. J Bayry M Thirion N Misra N Thorenoor S Delignat S Lacroix-Desmazes, et al. 2003 Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases Neurol Sci. 24 S217 21 10.1007/s10072-003-0081-7 14598046 (Pubitemid 37304326)
6. MD Kazatchkine SV Kaveri 2001 Immunomodulation of autoimmune and inflammatory Diseases with intravenous immune globulin NEJM. 345 747 55 10.1056/NEJMra993360 1:CAS:528:DC%2BD3MXmvFKjsLg%3D 11547745
7. A Mouzaki M Theodoropoulos I Gianakopoulos V Vlaha M-C Kyrtsonosis A Maniatis 2002 Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenia purpura (ITP) at presentation and their modulation by intravenous immunoglobulin (IVIg) treatment: thei role in prognosis Blood. 100 1774 9 1:CAS:528:DC%2BD38XmslyhtL8%3D 12176899
8. J Bayry MD Kazatchkine SV Kaveri 2007 Shortage of human intravenous immunoglobulin, reasons and possible solutions Nat Clin Pract Neurol. 3 3 120 1 10.1038/ncpneuro0429 17342189 (Pubitemid 46403934)
9. U Skansén-Saphir J Andersson L Björk C Ekberg TE Fehniger JI Henter, et al. 1998 Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells Scand J Immunol 47 3 229 35 10.1046/j.1365-3083.1998.00299.x 9519861 (Pubitemid 28153400)
10. D Amran H Renz G Lack K Bradley EW Gelfand 1994 Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin Clin Immunol Immunopathol 73 2 180 6 10.1006/clin.1994.1186 1:CAS:528: DyaK2MXitFCltrw%3D 7523013 (Pubitemid 24335398)
11. JF Modiano D Amran G Lack K Bradley C Ball J Domenico, et al. 1997 Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobulin Clin Immunol Immunopathol 83 1 77 85 10.1006/clin.1997.4329 1:CAS:528:DyaK2sXitlejt74%3D 9073539 (Pubitemid 27128399)
12. M Toyoda XM Zhang A Petrosian K Wachs A Moudgil SC Jordan 1994 Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin Transpl Immunol 2 4 337 41 10.1016/0966-3274(94)90012-4 1:CAS:528:DyaK2MXjvV2qsLc%3D 7704544
13. R Blasczyk U Westhoff H Grosse-Wilde 1993 Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations Lancet 341 789 90 10.1016/0140-6736(93)90563-V 1:STN:280:DyaK3s3gsVGksg%3D%3D 8096001 (Pubitemid 23096288)
14. H Grosse-Wilde R Blasczyk U Westhoff 1992 Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations Tissue Antigens. 39 74 7 10.1111/j.1399-0039.1992.tb01910.x 1:CAS:528:DyaK38Xks1yitL8%3D 1574801
15. M Ghio P Contini F Puppo F Indiveri 2000 The immunomodulatory effect of blood transfusions and intravenous immunoglobulins: the role of the soluble molecules of the Class-I major histocompatibility complex and of the Fas ligand Ann Ital Med Int 15 1 70 4 1:STN:280:DC%2BD3czgtFOisw%3D%3D 10842894
16. M Ghio L Ottonello P Contini M Amelotti C Mazzei F Indiveri, et al. 2003 Transforming growth factor-beta1 in supernatants from stored red blood cells inhibits neutrophil locomotion Blood. 102 1100 7 10.1182/blood.V102.3.1100 1:CAS:528:DC%2BD3sXlvFCmtLs%3D 12869488 (Pubitemid 36917812)
17. M Ghio P Contini C Mazzei S Brenci G Barberis G Filaci, et al. 1999 Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions Blood. 3 1770 7
18. M Ghio P Contini G Ubezio C Mazzei F Puppo F Indiveri 2008 Immunomodulatory effects of blood transfusions: the synergic role of soluble HLA Class I free heavy-chain molecules detectable in blood components Transfusion. 48 1591 7 10.1111/j.1537-2995.2008.01720.x 1:CAS:528:DC%2BD1cXhtVWmtrfL 18466172
19. M Ghio P Contini C Mazzei A Merlo G Filaci M Setti, et al. 2001 In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? Transfusion. 41 988 96 10.1046/j.1537-2995.2001.41080988.x 1:CAS:528:DC%2BD3MXmsVyiurY%3D 11493729 (Pubitemid 33642787)
20. + T lymphocytes and neutrophils following intravenous immunoglobulin treatment. Transfusion. 2009 (in press)
21. M Tanabe M Sekimata S Ferrone M Takiguchi 1992 Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain J Immunol. 148 3202 9 1:CAS:528:DyaK38Xkt1CnsLg%3D 1374450
22. MA Pellegrino NG AK C Russo S Ferrone 1982 Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules Transplantation. 34 18 23 10.1097/00007890-198207000-00004 1:STN:280:DyaL3s%2FhslCkug%3D%3D 6181590
23. H Nakajima J Samaridis L Angman M Colonna 1999 Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain J Immunol 162 1 5 8 1:CAS:528:DyaK1MXjt1Kmtw%3D%3D 9886363
24. L Ottonello M Ghio P Contini M Bertolotto G Bianchi F Montecucco, et al. 2007 Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I Transfusion. 47 1395 404 10.1111/j.1537-2995.2007.01268.x 1:CAS:528:DC%2BD2sXhtVWgurjK 17655583 (Pubitemid 47101062)
25. P Contini M Ghio A Merlo A Poggi F Indiveri F Puppo 2005 Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and Calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation J Immunol. 175 7244 54 1:CAS:528:DC%2BD2MXht1entrfL 16301629
26. F Puppo P Contini M Ghio S Brenci M Scudeletti G Filaci, et al. 2000 Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes Int Immunol 12 195 203 10.1093/intimm/12.2.195 1:CAS:528:DC%2BD3cXhsVyhsbg%3D 10653855
27. T Vassilev N Mihaylova E Voynova M Nikolova M Kazatchkine S Kaveri 2006 IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice Clin Exp Immunol 145 108 15 10.1111/j.1365-2249.2006.03098.x 1:CAS:528: DC%2BD28XpsFGrur0%3D 16792680 (Pubitemid 43893939)
28. NKA Prasad G Papoff A Zeuner E Bonnin MD Kazatchkine G Ruberti, et al. 1998 Therapeutic preparation of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving Fas apoptotic pathway J Immunol 161 3781 90 1:CAS:528: DyaK1cXmsFahtL0%3D 9759905
29. Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins-a review of the literature. Clin Rev Allergy Immunol. 10 Jul 2009 (in press)
30. JF Seite Y Shoenfeld P Youinou S Hillion 2008 What is the contents of the magic draft IVIg? Autoimmun Rev 7 6 435 9 10.1016/j.autrev.2008.04.012 18558358
31. J Bayry S Lacroix-Desmazes MD Kazatchkine SV Kaveri 2007 Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action Nat Clin Pract Rheumatol. 3 5 262 72 10.1038/ncprheum0481 1:CAS:528:DC%2BD2sXkslCltLY%3D 17471245 (Pubitemid 46711473)
32. G Zandman-Goddard M Blank Y Shoenfeld 2009 Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside Lupus. 18 10 884 8 10.1177/0961203309106921 1:CAS:528:DC%2BD1MXht1agtrnJ 19671787
33. R Gold M Stangel MC Dalakas 2007 Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues Nat Clin Pract Neurol. 3 1 36 44 10.1038/ncpneuro0376 1:CAS:528:DC%2BD2sXhsVSkt7k%3D 17205073 (Pubitemid 46056032)
34. F Nimmerjahn JV Ravetch 2008 Anti-inflammatory actions of intravenous immunoglobulin Annu Rev Immunol 26 513 33 10.1146/annurev.immunol.26.021607. 090232 1:CAS:528:DC%2BD1cXltlWktr0%3D 18370923 (Pubitemid 351600384)
35. T Tha-In J Bayry HJ Metselaar SV Kaveri J Kwekkeboom 2008 Modulation of the cellular immune system by intravenous immunoglobulin Trends Immunol. 29 12 608 15 10.1016/j.it.2008.08.004 1:CAS:528:DC%2BD1cXhsVWrsrbN 18926775
36. L Le Pottier T Sapir B Bendaoud P Youinou Y Shoenfeld JO Pers 2007 Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL Ann N Y Acad Sci 1110 426 32 10.1196/annals.1423.044 17911457 (Pubitemid 350043031)
37. GM Spaggiari P Contini A Dondero R Carosio F Puppo F Indiveri, et al. 2002 Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction Blood. 100 4098 107 10.1182/blood-2002-04-1284 1:CAS:528:DC%2BD38Xptlalsbg%3D 12393468 (Pubitemid 35396878)
38. MO Li RA Flavell 2008 TGF-beta: a master of all T cell trades Cell 134 392 404 10.1016/j.cell.2008.07.025 1:CAS:528:DC%2BD1cXhtVSis77N 18692464
39. SM Wahl 2007 Transforming growth factor-beta: innately bipolar Curr Opin Immunol 19 55 62 10.1016/j.coi.2006.11.008 1:CAS:528:DC%2BD2sXmtVeksg%3D%3D 17137775 (Pubitemid 46073697)
40. RJ Lories M Casteels-Van Daele JL Ceuppens SW Van Gool 2004 Polyclonal immunoglobulins for intravenous use induce interleukin 10 release in vivo and in vitro Ann Rheum Dis 63 6 747 8 10.1136/ard.2003.007138 1:CAS:528: DC%2BD2cXltFeku70%3D 15140788 (Pubitemid 38658411)
41. M Ghio P Contini S Negrini S Boero A Musso A Poggi 2009 Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity Eur J Immunol 39 12 3459 68 10.1002/eji.200939728 1:CAS:528:DC%2BD1MXhsFakurfF 19830740
42. R Spolski HP Kim W Zhu DE Levy WJ Leonard 2009 IL-21 mediates suppressive effects via its induction of IL-10 J Immunol 182 5 2859 67 10.4049/jimmunol. 0802978 1:CAS:528:DC%2BD1MXitFKhtbs%3D 19234181
43. MN Ince DE Elliott T Setiawan A Metwali A Blum HL Chen, et al. 2009 Role of T cell TGF-beta signaling in intestinal cytokine responses and helminthic immune modulation Eur J Immunol 39 7 1870 8 10.1002/eji.200838956 1:CAS:528:DC%2BD1MXosVakt7Y%3D 19544487
44. BC Yang HK Lin WS Hor JY Hwang YP Lin MY Liu, et al. 2003 Mediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by Fas signaling through a protein kinase A-independent pathway J Immunol 171 8 3947 54 1:CAS:528:DC%2BD3sXnvVOks7s%3D 14530312
45. E Fainardi R Rizzo M Castellazzi M Stignani E Granieri OR Baricordi 2009 Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis Hum Immunol 70 12 981 7 10.1016/j.humimm.2009.07.014 1:CAS:528:DC%2BD1MXhsVajurnP 19651179
46. CE Mapp S Ferrazzoni R Rizzo D Miotto M Stignani P Boschetto, et al. 2009 Soluble human leukocyte antigen-G and interleukin-10 levels in isocyanate-induced asthma Clin Exp Allergy 39 6 812 9 10.1111/j.1365-2222.2009. 03215.x 1:CAS:528:DC%2BD1MXnsF2jsLg%3D 19302248